Biotheus (普米斯生物技术) is a biotech company that develops antibody-based therapeutics for cancer and metabolic disease. Its R&D capabilities include antibody discovery, process development, and analytical assessment platforms. The company also studies the mechanisms of Treg cells and innate immunity in cancer.
Biotheus has raised $114.5 million in total funding. Investors of Biotheus include Huajin Capital, Shiyu Capital, HighLight Capital, New Alliance Capital, General Atlantic and 8 more.
Location: China
Investors 1
| Date | Name | Website |
| - | New Allian... | nac-capita... |
Mentions in press and media 5
| Date | Title | Description | Source |
| 15.03.2024 | Biotheus Expanded Their Partnership with Hansoh Pharma for D... | ZHUHAI, China, March 15, 2024 /PRNewswire/ -- On March 14, 2024, Biotheus Inc. (Biotheus), a clinica... | en.prnasia... |
| 06.11.2023 | Biotheus Enters Into Strategic Partnership with BioNTech to ... | Bispecific Antibody Candidate PM8002 demonstrated encouraging data at this year's ASCO Annual Meetin... | en.prnasia... |
| 20.07.2023 | Biotheus Announces Strategic Research Collaboration and Worl... | ZHUHAI, China, July 20, 2023 /PRNewswire/ -- Biotheus Inc. ("Biotheus"), a clinical-stage ... | en.prnasia... |
| 15.11.2022 | Biotheus has entered into a license and collaboration agreem... | ZHUHAI, China, Nov. 15, 2022 /PRNewswire/ -- Biotheus Inc., a clinical-stage biotech company focused... | en.prnasia... |
| 03.12.2021 | Biotheus' Bifunctional Therapeutic PM8001 has been Approved ... | ZHUHAI, China, Dec. 3, 2021 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-P... | en.prnasia... |